Open data on public expenditure — datasets, categories and a SPARQL endpoint for research and analysis

Greece’s Public Healthcare Spending on Pharmaceuticals by Region

Pharmaceutical expenditure is one of the clearest ways to examine how public healthcare resources move through Greece. Payments for medicines can reveal differences in population needs, hospital activity, reimbursement patterns, procurement practices, and the administrative routes used to fund care. Yet regional comparisons require careful interpretation because a payment location does not always represent the place where a patient received treatment.

Publicspending.net supports this type of investigation by bringing government payment records into a searchable, standardized environment. Its datasets can help researchers examine pharmaceutical suppliers, public bodies, transaction values, dates, and geographic references across Greece. The result is a practical foundation for studying medicine expenditure alongside demographic, clinical, and economic indicators.

A useful analysis separates the amount paid from the reason behind the payment. A large total in Attica may reflect its population and concentration of major hospitals, while a high per-capita figure in a smaller region may indicate specialized services, seasonal demand, or a limited number of unusually large contracts. Regional pharmaceutical spending becomes meaningful when these factors are considered together.

What The Spending Data Can Reveal

Government expenditure on pharmaceuticals may appear in several forms. Public hospitals can purchase medicines directly, health insurance institutions can reimburse prescriptions, and public agencies can pay wholesalers, pharmacies, distributors, or manufacturers. These payment channels may be recorded under different classifications, even when they relate to similar products or treatment pathways.

The recipient named in a transaction is another important clue. A payment to a pharmaceutical company may represent a supply contract, while a payment to a pharmacy may relate to reimbursed outpatient prescriptions. Payments to hospitals or regional health authorities can involve stock purchases, emergency procurement, or centralized distribution. Treating every pharmaceutical-related transaction as equivalent would obscure these distinctions.

Regional analysis can therefore answer several different questions. Which areas receive the largest total payments? Which regions record the highest expenditure per resident? Where are public hospitals or health authorities the dominant purchasers? Are spending patterns stable across years, or do they change after a new procurement program, reimbursement policy, or public health event?

Greece’s Administrative And Healthcare Geography

Greece is commonly divided into 13 administrative regions, including Attica, Central Macedonia, Crete, Western Greece, Thessaly, and the North and South Aegean. These regions do not all have the same population, hospital capacity, age structure, tourism activity, or access to specialized care. Those differences shape pharmaceutical demand and the way public payments are distributed.

Attica contains Athens and a large share of the country’s tertiary hospitals, specialist clinics, and administrative institutions. Central Macedonia, centered around Thessaloniki, also has a major concentration of healthcare services. A transaction assigned to either region may support patients referred from other parts of Greece, meaning regional totals can reflect service concentration rather than local consumption alone.

Island regions require additional care in interpretation. The North Aegean, South Aegean, and Ionian Islands may experience seasonal population changes, transport costs, and different supply arrangements. A single centralized contract or delivery to a major hospital can produce a significant annual value relative to the resident population. Regional comparisons should therefore use multi-year data and, where possible, complementary indicators such as hospital beds, admissions, prescription volume, and age distribution.

Building A Reliable Regional Measure

The first step is to define which payments belong in the analysis. A narrow measure might include only transactions whose descriptions explicitly identify medicines or pharmaceutical products. A broader measure could include medical supplies, hospital pharmacy services, vaccines, and related distribution costs. The selected definition should remain consistent across regions and years.

The second step is geographic normalization. Public records may identify a region through the address of a buyer, the location of a supplier, a municipality, a hospital code, or an administrative authority. These fields can produce different maps. Supplier headquarters, for example, may cluster in Athens even when products are delivered throughout the country. Buyer location is often more useful for public healthcare allocation, but it still needs to be documented.

Researchers can inspect records through the SPARQL endpoint, which enables structured queries across linked entities and classifications. A query might group payments by region, year, recipient type, or spending category, then isolate pharmaceutical transactions for a more focused comparison. Ontology-based links can also help distinguish organizations, locations, and payment concepts that appear under different names in source documents.

Comparing Regional Spending Patterns

Absolute expenditure is useful for understanding the scale of public purchasing, but it is strongly influenced by population and healthcare infrastructure. Per-capita spending provides a different perspective, while the share of pharmaceutical expenditure in total healthcare payments indicates the relative importance of medicines within each region’s public budget.

The following measures can be used together rather than treated as interchangeable:

Measure What It Helps Show Main Interpretation Risk
Total pharmaceutical payments Overall public purchasing volume Favors highly populated regions and major hospitals
Spending per resident Approximate regional intensity of expenditure Can be distorted by referral care and small populations
Pharmaceutical share of healthcare payments Relative budget priority given to medicines Depends on which healthcare categories are included
Number of transactions Procurement frequency and payment activity Many small payments may equal one large contract
Median transaction value Typical payment size Does not show the impact of exceptional contracts
Year-over-year change Shifts in spending over time A single year may reflect timing or accounting changes

A strong comparison presents at least two of these measures. For example, Attica may lead in total payments but rank lower in per-capita spending than a smaller region with a specialized facility. Conversely, a region with a high per-resident figure may simply have received a large one-time hospital delivery. Examining the median transaction value and annual sequence can help identify that distinction.

Inflation and changes in medicine prices should also be considered. A rise in nominal expenditure does not necessarily mean that more medicines were purchased. Researchers can compare payment growth with transaction counts, quantities when available, and relevant price indices. If product-level data are absent, the analysis should describe changes as payment growth rather than increased pharmaceutical consumption.

Suppliers, Hospitals, And Public Buyers

Supplier concentration can reveal how public pharmaceutical procurement is organized. If a small number of companies receive a large share of regional payments, the pattern may reflect framework agreements, specialized medicines, or centralized purchasing. It may also indicate that the recorded supplier is acting as an intermediary for deliveries to several facilities.

Hospital-level analysis adds useful detail. A region with several major hospitals may show a broad distribution of payments across institutions, while a smaller region may be dominated by one public hospital or health authority. Comparing the number of buyers with total expenditure can distinguish a widespread pattern from a single-institution effect.

Payment timing matters as well. Large transactions near the end of a fiscal year may be linked to budget execution schedules rather than an abrupt change in medical demand. Delayed invoices, contract renewals, and multi-year procurement arrangements can make annual totals appear uneven. Monthly or quarterly trends provide a better view of whether a regional pattern is persistent.

Interpreting Equity And Access

Regional pharmaceutical expenditure can contribute to discussions about healthcare equity, but spending alone cannot establish whether access is better or worse. A low total may reflect efficient procurement, a younger population, private provision, limited reporting, or reduced access to treatment. A high total may indicate greater need, advanced services, or costly medicines for a relatively small patient group.

Per-capita calculations should be supplemented with indicators of need. Useful comparisons may include the proportion of older residents, chronic disease prevalence, hospital admissions, cancer treatment capacity, disability rates, and distance from specialist services. Seasonal population estimates can be especially relevant for tourist regions, where resident counts may understate the people served during part of the year.

The geographic level also affects the equity story. National agencies can purchase medicines centrally and distribute them across multiple areas, making the original payment record appear concentrated in one location. A regional map should therefore distinguish between administrative spending, delivery location, and patient location whenever the source data permit. Clear documentation prevents a procurement map from being mistaken for a map of patient need.

Practical Checks Before Drawing Conclusions

A transparent workflow makes regional pharmaceutical analysis more credible. Start by recording the source dataset, coverage period, currency, classification rules, geographic field, and treatment of refunds or negative payments. Preserve the original identifiers so that aggregated results can be traced back to individual records.

Then test the data for duplicates, missing locations, inconsistent organization names, and unusually large transactions. A supplier may appear under several spellings, while the same hospital may be represented by a legal entity, an acronym, and a local name. Standardization improves totals, but every transformation should be documented so that another researcher can reproduce it.

Useful safeguards include:

These checks also make public communication more accurate. A chart should identify whether it displays gross payments, net payments, awarded contract values, or executed expenditure. It should show the period and geographic definition, since a polished visualization can still mislead when the underlying measure is ambiguous.

Turning Open Records Into Better Analysis

Open spending data are most valuable when they can be connected with other public information. Population statistics can support per-capita measures, while hospital registries can help identify referral centers and specialist capacity. Health outcome data may provide context for whether spending patterns correspond to differences in treatment needs, although correlation should not be presented as proof of effectiveness.

Researchers can also examine procurement behavior. Repeated payments to the same supplier, changes in contract size, and differences between regions may point to centralized purchasing or fragmented local procurement. Comparing pharmaceutical expenses with other hospital categories can show whether a regional budget is medicine-intensive or simply large across all forms of care.

For journalists, civil society groups, and public officials, the value lies in making the underlying evidence inspectable. A regional ranking should link back to data definitions and source records, while downloadable files allow others to test the calculations. Publicspending.net’s structured resources make it possible to move from a headline figure to the organizations, transactions, and classifications that produced it.

Use the available Greek payment records to build a documented regional comparison, validate the geography, and publish results with clear per-capita and time-based context. Exploring the data through Publicspending.net can turn scattered pharmaceutical transactions into evidence that supports more informed debate about healthcare allocation, procurement, and access across Greece.